Destiny Pharma plc (GB:DEST) has released an update.
Destiny Pharma plc’s Phase 2b clinical trial results revealed that patients treated with XF-73 Nasal gel required significantly fewer post-surgical antibiotics compared to the placebo group. These findings underscore the potential of XF-73 in enhancing antimicrobial stewardship and patient safety by reducing infection risk and maintaining antibiotic efficacy. The company plans to present further data at the ID Week conference and is preparing for Phase 3 studies to seek regulatory approval.
For further insights into GB:DEST stock, check out TipRanks’ Stock Analysis page.
